![]() |
|
|
Vol. 284, Issue 1, 61-65, 1998
Department of Pharmacology, Cornell University Medical College, New
York, New York (H.H.S., Y.S., D.W.);
Department of Reproductive Biology
and Obstetrics and Gynecology, Case Western Reserve University and
MetroHealth Medical Center, Cleveland, Ohio (J.F.C., N.O.);
The Charles
B. Stout Neuroscience Mass Spectrometry Laboratory (D.M.D., O.O.G.,
J.L.T., R.B.) and Departments of
Neurology and Biochemistry (D.M.D.),
University of Tennessee, Memphis, Tennessee; and
Laboratory of Chemical
Biology and Peptide Research, Clinical Research Institute of Montreal,
Montreal, Quebec, Canada (P.W.S.)
Although synthetic opioid peptide analogs have been used extensively to
study the functional roles of opioid receptors, little is known about
their in vivo disposition. Our goal was to develop novel
opioid drugs with limited transfer across the placenta. DALDA
(Tyr-D-Arg-Phe-Lys-NH2) is a potent and highly
selective mu agonist that is quite polar because of its
3+ charge at physiological pH. It can therefore be expected that the
distribution of DALDA across the placenta would be highly restricted.
In this study, we determined the pharmacokinetics and placental
transfer of DALDA after systemic administration in sheep. DALDA was
infused intravenously to four nonpregnant and four pregnant sheep at a
dose of 0.6 mg/kg/hr for 4 hr. Steady state plasma levels of DALDA were
5436 ± 464 ng/ml in nonpregnant sheep and 5214 ± 661 ng/ml
in pregnant sheep. A one-compartment open model provided an excellent
fit for nonpregnant and pregnant plasma data. The apparent volume of
distribution was estimated to be 45.6 ± 4.4 and 59.2 ± 7.9 ml/kg in nonpregnant and pregnant animals, respectively. There was no
difference in the elimination half-life of DALDA in nonpregnant
(1.4 ± 0.1 hr) and pregnant (1.7 ± 0.2 hr) animals, and
clearance was also similar in nonpregnant (23.1 ± 1.7 ml/kg/hr)
and pregnant (23.7 ± 1.3 ml/kg/hr) animals. These data suggest
that the distribution of DALDA is restricted to plasma volume and that
its disposition is not altered in pregnancy. DALDA was not detected in
any of the fetal plasma samples (<50 ng/ml), indicating that fetal
plasma concentration is <1% of maternal concentration. The highly
restricted placental distribution of DALDA suggests that it may be a
promising opioid drug for obstetrical use.
This article has been cited by other articles:
![]() |
H. H. Szeto, J. L. Lovelace, G. Fridland, Y. Soong, J. Fasolo, D. Wu, D. M. Desiderio, and P. W. Schiller In Vivo Pharmacokinetics of Selective {micro}-Opioid Peptide Agonists J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 57 - 61. [Abstract] [Full Text] |
||||